Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(9): e24398.
Published online 2011 September 15. doi:  10.1371/journal.pone.0024398
PMCID: PMC3174172

Protection from Experimental Cerebral Malaria with a Single Dose of Radiation-Attenuated, Blood-Stage Plasmodium berghei Parasites

Fabio T. M. Costa, Editor



Whole malaria parasites are highly effective in inducing immunity against malaria. Due to the limited success of subunit based vaccines in clinical studies, there has been a renewed interest in whole parasite-based malaria vaccines. Apart from attenuated sporozoites, there have also been efforts to use live asexual stage parasites as vaccine immunogens.

Methodology and Results

We used radiation exposure to attenuate the highly virulent asexual blood stages of the murine malaria parasite P. berghei to a non-replicable, avirulent form. We tested the ability of the attenuated blood stage parasites to induce immunity to parasitemia and the symptoms of severe malaria disease. Depending on the mouse genetic background, a single high dose immunization without adjuvant protected mice from parasitemia and severe disease (CD1 mice) or from experimental cerebral malaria (ECM) (C57BL/6 mice). A low dose immunization did not protect against parasitemia or severe disease in either model after one or two immunizations. The protection from ECM was associated with a parasite specific antibody response and also with a lower level of splenic parasite-specific IFN-γ production, which is a mediator of ECM pathology in C57BL/6 mice. Surprisingly, there was no difference in the sequestration of CD8+ T cells and CD45+ CD11b+ macrophages in the brains of immunized, ECM-protected mice.


This report further demonstrates the effectiveness of a whole parasite blood-stage vaccine in inducing immunity to malaria and explicitly demonstrates its effectiveness against ECM, the most pathogenic consequence of malaria infection. This experimental model will be important to explore the formulation of whole parasite blood-stage vaccines against malaria and to investigate the immune mechanisms that mediate protection against parasitemia and cerebral malaria.


Studies of natural immunity to human malaria and evidence from experimental models suggest that repeated exposure to malaria parasites is the most effective method to induce immunity against malaria [1]. Likewise, the most successful experimental malaria vaccine is based on repeated immunizations with radiation-attenuated malaria sporozoites delivered by multiple bites from infected mosquitoes [2]. In Plasmodium falciparum malaria, the immunity induced by irradiated sporozoites is species-dependent yet it is cross-protective against different parasite strains [3]. Attenuated parasite vaccines have long been an interest for malaria [1], and so far the major efforts to develop such whole organism vaccines have focused on generating attenuated sporozoites by radiation [4], [5], chemical [6], drug cure [7], or targeted gene disruption methods [8], [9], [10]. In comparison, less research has been done on live vaccines against the malaria blood stages which are responsible for the clinical symptoms of the disease [1], [11]. However, attenuated blood-stage vaccines produced by radiation [12], [13] gene disruption [14], [15], [16], and drug cure methods [17], [18], have demonstrated effectiveness for protection against parasitemia and symptoms of severe malaria.

In the current study, we investigate the effectiveness of a radiation-attenuated blood-stage parasites for protection against parasitemia and severe disease in experimental models of malaria. We used the highly virulent murine malaria parasite Plasmodium berghei ANKA (Pb-A) which, depending on the mouse genetic background, produces two distinct yet uniformly fatal pathologies. In CD1 mice, a few virulent blood-stage Pb-A are sufficient to initiate a patent infection that ultimately produces high parasite parasitemia, severe anemia, and death. In contrast, C57BL/6 mice infected with Pb-A are susceptible to experimental cerebral malaria (ECM) which is characterized by an early onset of neurological defects, coma, and death associated with a relatively low parasitemia [19], [20]. We show that a single, non-adjuvanted immunization with a high-dose of radiation-attenuated, blood-stage Pb-A parasites protected CD1 mice from parasitemia and severe disease, and it protected C57BL/6 mice from ECM. Protection from ECM was associated with an anti-parasite antibody response and a reduced IFN-γ response in the spleen during a virulent infection.

Materials and Methods

Mice, parasites, and immunizations

Ethics statement

6–8 week old female C57BL/6 and Swiss-CD1 mice were used in accordance with the animal study protocols (#2009-22, 2007-14) approved by the Food and Drug Administration, Center for Biologics Evaluation and Research Institutional Animal Care and Use Committee. Blood-stage Plasmodium berghei ANKA (Pb-A) parasites (an uncloned parasite line) from −70 C glycerolyte stocks were injected intraperitoneally into donor mice with the same genetic background of the experimental mice [19]. Parasitemia was monitored by Giemsa-stained thin blood smears and total RBC were counted by hemocytometer. For challenge infections, 104 parasitized RBC (pRBC) were injected intravenously (iv) via the tail vein. Mice were evaluated for ECM symptoms and the ability to survive beyond day 10 post infection as previously described [20]. For immunization, 103 or 107 irradiated pRBC were injected into mice iv as described in the text.

Radiation-attenuation of parasite growth

To attenuate parasite growth, freshly harvested Pb-A pRBC were diluted in phosphate buffered saline (PBS) to a concentration of 5×107 pRBC per milliliter (ml). One ml aliquots of parasites were then immediately exposed to a Cesium-137 source for various time periods at room temperature in a Gammacell 1000 irradiator. Radiation dose was calculated from the machine-specific estimate of 1505 Rads per minute.

Spleen cell culture

Culture media and buffers were obtained from Invitrogen unless specified otherwise. Freshly isolated mouse splenocytes were plated in triplicate in 24-well tissue culture plates. For parasite antigen stimulation, pRBC were lysed with 4 freeze/thaw cycles, and 1×106 pRBC equivalents were added per well. Control wells were stimulated with an equal number of lysed uninfected RBC, or with medium alone. Cells were cultured for 72 hours, then supernatants were collected by centrifugation and stored at −70 C. Interferon-gamma protein levels were assayed in culture supernatants using the Ready-Set-Go sandwich ELISA kit (Ebioscience) according to the manufacturer's instructions with a stated detection sensitivity limit of 15 pg/ml.

Brain sequestered cells

Brain cell suspensions were prepared as described [21]. Briefly, the brains of anesthetized mice were perfused intracardially with Hank's Buffered Saline Solution (HBSS), removed, and then pushed through 70 micron filters. Cell suspensions were centrifuged at 400× g at 21 C, and the pellets were resuspended in RPMI/FCS with 0.5 mg/ml collagenase D (Roche), 3 units/ml DNAse (Roche), and 5 mM MgCl2. The samples were rotated for 60 minutes at room temperature, allowed to stand for 10–15 minutes, and the supernatants were collected. Each sample was brought to a final concentration 33% Percoll (Sigma-Aldrich) and then under-layered with 70% Percoll/HBSS. The gradients were centrifuged at 515× g for 30 minutes at 21 C, the cells were collected from the 33/70% interface, and washed with HBSS. Residual red blood cells were lysed with ACK lysis buffer, and the samples were washed twice in RPMI/FCS before preparation for multicolor flow cytometry.

Flow Cytometry

Brain cells (pooled from 4 mice within each group) were stained with the Fixable Viability Dye eFluor 660 (eBioscience) according to the manufacturer's instructions. Cells were blocked with TruStain fcX anti-mouse CD16/32 (Biolegend) and then stained in HBSS, 1% BSA on ice for 30 minutes with the following anti-mouse antibodies: AlexaFluor 488-CD8a (Biolegend), PE-NK1.1 (Biolegend), PerCP-CD11b (Biolegend), APC-eFluor 780-CD45 (eBioscience), eFluor 450-CD3, AlexaFluor488-CD44 (Biolegend), PE-CD62L (Biolegend), PerCP-CD69 (Biolegend), APC-eFluor 780-CD8a (eBioscience), and then fixed with IC fixation buffer (eBioscience). Samples were read on an LSRII cytometer (BD). Fluorescence-minus-one (FMO) controls were used to set population gates for each panel. Data analysis was performed in FlowJo v7.5 software. 36,000–160,000 cells were analyzed for each pooled brain sample.

Serum antibody ELISA

Mouse sera were pooled within treatment groups and then stored at −20 C. Pb-A-specific antibodies were detected by endpoint ELISA at O.D. 405 nm as previously described [22]. Positive signal cut-off was defined as two times the mean O.D. value from normal sera. Antibody titer was determined as the highest sample dilution which produced an O.D. value greater than or equal to the cut-off.


Graphs, survival analysis, and statistics were performed in GraphPad Prism 5 (Graphpad Software, Inc). Two-sided p-values and 95% confidence intervals are reported. Survival to day 10 in ECM experiments was analyzed using Fisher's exact test as previously described [20]. For Two-Way ANOVA, the Bonferroni correction for multiple comparisons on post tests was used.


Determination of the radiation dose necessary to attenuate blood-stage Pb-A

To determine the radiation dose necessary to attenuate Pb-A growth and virulence, parasitized red blood cells (pRBC) were exposed to increasing doses of radiation. Parasite attenuation was evaluated by intravenously (iv) injecting 107 irradiated pRBC into CD1 mice and then monitoring the mice for parasite growth and disease symptoms (Figure 1). Parasites irradiated at doses up to 60 kilorads reproduced in the mice, and these mice developed patent parasitemias within 7 days (Figure 1, Ctrl, 10–60 krad groups). Higher radiation doses produced greater evidence of parasite attenuation. All of the mice that received 80 kilorad irradiated parasites (14/14) were free of patent infection through day 7, and 70% (10/14) did not develop detectable parasitemias or disease symptoms for the duration of the experiment (Figure 1, open circles). However, by day 14, 30% (4/14) of the mice that had been injected with 80 kilorad irradiated parasites developed patent infections and severe disease symptoms. This suggested that the 80 kilorad irradiation attenuated the growth and virulence of the majority of the parasites, but that a few residual parasites escaped attenuation and were eventually able to establish fulminant infections.

Figure 1
Determination of the radiation dose necessary to attenuate blood-stage Pb-A parasites.

In contrast, all of the mice (10/10) that received 100 kilorad irradiated parasites (Figure 1, open squares, solid line) remained free from patent parasitemia and disease symptoms for the duration of the experiment. This demonstrated that the 100 kilorad dose was sufficient to cause the complete attenuation of blood-stage Pb-A parasites, and so the 100 kilorad dose was chosen to attenuate parasite growth in subsequent experiments.

Attenuated Pb-A blood-stage parasites induce protection against parasitemia and severe disease in CD1 mice

We determined whether iv immunization with 103 or 107 irradiated Pb-A blood-stage parasites (IrrPb) protected CD1 mice against parasitemia and/or severe disease after a challenge infection with virulent blood-stage Pb-A (Figure 2A). No residual IrrPb were detected in the blood smears of immunized mice on the day before the virulent challenge. After challenge, the group immunized with 103 IrrPb displayed an uncontrolled blood infection similar to naïve mice, and none of these mice (0/5) survived beyond day 12 without developing severe disease symptoms. In contrast, the group immunized with 107 IrrPb (n = 5, Figure 2A, open squares) showed evidence of controlling the blood stage infection after challenge, and reached a peak mean parasitemia of 7.3% on day 8 with only one of these mice developing severe disease symptoms on this day. 80% (4/5) of the 107 IrrPb immunized mice did not develop severe malaria symptoms and their mean parasitemias decreased to low or undetectable levels by day 21 (Figure 2A). These mice remained free from disease symptoms for 5 months of observation after challenge. This is strong evidence that a single immunization with 107 IrrPb protects CD1 mice from virulent challenge, while a similar immunization with 103 IrrPb is not protective.

Figure 2
Protection from parasitemia and severe disease in CD1 mice after immunization with irradiated blood-stage Pb-A.

To test whether more than one immunization of attenuated parasites would improve protection, groups of CD1 mice were immunized with 103 or 107 IrrPb and 24 days later they were given a booster immunization with an equal number of IrrPb. The mice were then challenged with virulent Pb-A pRBC and parasitemia was monitored (Figure 2B). Similar to naïve mice (Figure 2B, filled circles), mice immunized twice with 103 IrrPb (Figure 2B, open triangles) displayed continually increasing parasite growth after challenge. Mice that had received two immunizations with 107 IrrPb (n = 5, Figure 2B, open squares) developed a peak mean parasitemia of 9.7% on day 8 after challenge, and by day 21, all of these mice (5/5) had controlled parasitemias down to low or undetectable levels. Similar to the results from single immunization experiments (Figure 2A), these results demonstrated that two immunizations with 107 IrrPb was protective in a model of acute blood-stage disease, while two immunizations with 103 IrrPb was not protective.

Attenuated Pb-A blood-stage parasites induce protection against ECM in C57BL/6 mice

Since immunization with IrrPb protected CD1 mice from parasitemia and acute blood-stage disease, we wanted to test whether a similar immunization regimen would protect C57BL/6 mice from the symptoms of experimental cerebral malaria (ECM). Groups of C57BL/6 mice immunized once with 103 or 107 IrrPb were challenged with virulent Pb-A pRBC and then monitored for the symptoms of ECM, survival beyond day 10, and blood parasitemia (Figures 3A and 3B). After challenge, 10% (1/10) of naïve mice (filled circles) and 12% (2/17) of mice immunized with 103 IrrPb (open triangles) survived beyond day 10 (Figure 3A). The mean parasitemia levels were below 10% for all groups before day 10 (Figure 3B). This is consistent with the ECM model in C57BL/6 mice, and suggested that immunization with 103 IrrPb did not offer any significant protection from ECM or parasitemia. In contrast, 81% (17/21) of mice immunized with 107 IrrPb (open squares) did not display any symptoms of ECM and survived beyond day 10 (Figure 3A, p = .0003 survival to day 10, naïve vs. 107 IrrPb immunized mice). This is very strong evidence that a single immunization with 107 IrrPb induced a high level of protection from ECM. Similar to other reports in this model [23], the mice that were protected from ECM and survived beyond day 10 still succumbed to hyperparasitemia by the end of the experiment (Figure 3B).

Figure 3
Protection from experimental cerebral malaria (ECM) in C57BL/6 mice after immunization with IrrPb.

To test whether two immunizations with IrrPb enhanced protection from ECM, C57BL/6 mice immunized twice with 103 or 107 IrrPb with a 28 day interval were challenged with virulent Pb-A pRBC (Figures 3C and 3D). After challenge, 20% (1/5) of naïve mice (filled circles) and none (0/10) of the mice immunized twice with 103 IrrPb (open triangles) survived to day 10, indicating that two immunizations did not improve the ability of 103 IrrPb to induce protection against ECM in this model. In contrast, 100% (10/10) of the mice immunized twice with 107 IrrPb (open squares) survived to day 10 after challenge (p = .0037, survival to day 10, naïve vs. 107 IrrPb boost immunized mice), which was strong evidence that two immunizations with 107 IrrPb protected from ECM. Immunization with 107 IrrPb did not protect against parasitemia in the C57BL/6 model since all mice that survived ECM eventually succumbed to high parasite levels (Figure 3B and D).

Protective immune responses associated with attenuated Pb-A blood-stage parasites

We next investigated the antibody and cellular responses induced by a single immunization with 103 or 107 IrrPb for correlations with the protection from ECM. Pb-A-specific IgG antibodies were not detected in sera from 103 IrrPb immunized mice with or without challenge, similar to naïve mice (Figure 4A and B). In contrast, Pb-A-specific IgG antibodies were detected in sera from 107 IrrPb immunized mice before challenge (Figure 4A), and antibody titers were detected at levels 1–2 log-fold higher in the sera from these mice during a virulent challenge (Figure 4B). Thus, the immunization with 107 IrrPb which was protective against ECM generated a parasite-specific serum antibody response, while the non-protective immunization with 103 IrrPb did not produce a measureable antibody response.

Figure 4
Immune responses associated with IrrPb immunization in C57BL/6 mice.

Parasite-specific IFN-γ responses were also measured in spleen cell cultures from immunized mice before or during a virulent infection (Figure 4C and 4D). Among uninfected mice, IFN-γ was not detected in samples from naïve or 103 IrrPb immunized mice (Figure 4C, n.d). However, samples from uninfected 107 IrrPb immunized mice did produce IFN-γ protein in response to Pb antigen stimulation (Figure 4C, black bar, PbAg), indicating that immunization with only the higher dose of IrrPb was able to induce IFN-γ production by spleen cells in the absence of a virulent infection.

During a virulent Pb-A challenge infection, the spleen cells from naïve mice and 103 IrrPb immunized mice produced the highest levels of IFN-γ (Figure 4D). As described in Figure 3, these groups had the highest prevalence of ECM, and this pattern of IFN-γ expression is consistent with published reports. In contrast, during a virulent infection the spleen cells from the 107 IrrPb immunized mice produced significantly less IFN-γ in comparison with cells from naïve mice, whether they were stimulated in vitro with parasite antigen (Figure 4D, black bars. p<.0001, naïve vs. 107 IrrPb, mean difference 596 (411, 781) pg/ml) or unstimulated (Figure 4D, white bars. p<.0001, naïve vs. 107 IrrPb, mean difference 534 (349, 719) pg/ml).

Since a single immunization with 107 IrrPb 1) protected mice from ECM, 2) produced a parasite-specific antibody response, and 3) was associated with a decreased IFN-γ response in the spleen during infection, we decided to examine the response to this immunization further. Consistent with other studies using attenuated blood-stage Pb-A, the average spleen weights from immunized challenged mice (Figure 5, 107 IrrPb Challenged) were 1.5–2-fold larger than the spleen weights from naïve challenged mice (p<.001, mean difference = 0.17 (0.09, 0.24) grams), suggesting an increased splenic activity during infection. In the absence of a virulent Pb-A challenge, the spleens from immunized mice were not significantly heavier than the spleens from naïve mice (Figure 5, Unchallenged).

Figure 5
Spleen weights of mice immunized with IrrPb increase during a virulent infection.

We next examined the immune cell subtypes in the brains of mice after a single immunization with 107 IrrPb for correlations with the protection from ECM (Figure 6). As reported previously, CD8 T cells and macrophages were prominent in the brain vasculature of Pb-A infected naïve mice on day 6 (Figure 6A, and 6B, Naïve Challenged, solid black and hatched bars, 4.2+/−2.1% and 2.6+/−0.7% of isolated cells, respectively). Microglia, NK cells, and NKT cells were detected at low frequencies in these experiments, and significant differences were not detected among any of the sample groups (Figure 6B). The number of total cells and specific cell types analyzed in each group are shown in Figure 6C.

Figure 6
Flow cytometry analysis of cell subtypes in brains of mice immunized with 107 IrrPb.

Surprisingly, CD8 T cells and macrophages were also detected in the brains of mice immunized with 107 IrrPb on day 6 after challenge, and their frequencies were not significantly different from those observed in naïve mice during infection (Figure 6B, 107 IrrPb Challenged, solid black and hatched bars, 3.3+/−0.2% and 2.0+/−0.6% of isolated cells, respectively). In agreement with previous reports in the Pb-A model, the brain-sequestered CD8 T cells from infected naïve and immunized mice largely had a CD44+ CD62L− effector phenotype (Figure 6D, hatched bars), and approximately 55% of these effector cells were also positive for the early activation marker CD69+ (Figure 6E) consistent with active, tissue invading cells. This indicated that immunization with 107 IrrPb protected mice from ECM after a virulent Pb-A challenge without significantly reducing the infiltration of CD 8 T cells into the brain vasculature.


Some of the earliest malaria vaccine studies in experimental models were based on the use of irradiation-attenuated whole malaria parasites [24]. However, due to the perceived difficulties related to their safety and large scale production, the whole parasite approach was not considered to be a practical vaccine strategy. In recent years, the limited success of sub-unit based vaccines in clinical studies has reignited the interest in whole parasite based malaria vaccines [11]. Notwithstanding their potential value as candidate vaccines, studies with radiation-attenuated parasites offer an excellent opportunity to explore host pathogenesis and to examine the immune mechanisms induced by protective vaccines against malaria.

In the current study, a single, non-adjuvanted immunization with 107 irradiated blood-stage parasites protected CD1 mice from parasitemia and severe disease, while up to two immunizations with 103 irradiated parasites were not protective. This anti-parasite immunity is consistent with previous studies of irradiated blood-stage malaria parasites that showed protection from parasitemia and severe malaria anemia in different model systems [12], [13], [24], [25], [26]. The protection in the previous studies was achieved without adjuvants, and it also required the intravenous delivery of large numbers of blood-stage parasites.

To our knowledge, the current study is the first to also demonstrate the effectiveness of irradiated blood-stage parasites for protection against ECM, the most pathogenic consequence of malaria infection. A single immunization with 107 irradiated parasites protected against ECM, while two immunizations of 103 irradiated parasites did not protect. However, in contrast to immunized CD1 mice, the immunized C57BL/6 mice that had acquired anti-disease immunity against ECM did not acquire anti-parasite immunity. Similar observations have been noted in other experimental studies [23], [27], suggesting that anti-disease immunity and anti-parasite immunity act through distinct mechanisms. This notion is further supported by the observations of distinct immune mechanisms that confer immunity against severe malaria and parasitemia in adults living in endemic areas [28], [29].

The mechanism of protection in this study is not known, and thus it is not clear what relative roles humoral and cellular responses may have played for this protection. The protective immunization against ECM in this study was associated with a parasite-specific antibody response that increased following a boost during a challenge infection. However, whether these antibodies played any role against protection from ECM (C57Bl/6 mice) or parasitemia (CD1 mice) is not clear. In previous studies, antibody responses have been shown to be important to some whole parasite vaccines [14], [16], and it has been proposed that part of their protective effects may come from an increased clearance of opsonized parasites [30]. In the current study, the immunized ECM-protected mice did not have significantly lower blood parasitemia levels compared to non-protected mice, suggesting that bulk parasite clearance is unlikely to fully explain protection. However, the spleen sizes of protected mice increased 2-fold during a virulent infection, and since this can be indicative of increased parasite clearance and/or immune cell recruitment, further experiments will be necessary to address this question in detail. The ECM-protective immunization was also associated with a reduced parasite-specific IFN-γ response in the spleen during a virulent infection. In mice that have a Th1 bias such as C57BL/6, splenic IFN-γ production during a blood-stage Pb-A infection is thought to promote inflammatory responses that contribute to ECM pathology [31]. In contrast, the non-protective immunization in this study did not stimulate anti-parasite antibodies and it only modestly reduced parasite-specific IFN-γ expression during an infection, indicating that it was less effective at stimulating both antibody and cellular responses.

While elevated levels of splenic IFN-γ during the fulminant phase of Pb-A infection in mice are associated with susceptibility to ECM, a very early IFN-γ response in the spleen during infection has been associated with resistance to ECM [32]. In a previous study, it was proposed that CD 8+ T cells were a source of the early splenic IFN-γ responses during Pb-A infection, and the authors provided evidence that NK cells, NKT cells, and γδ T cells did not significantly contribute to this IFN-γ signal. In the current study, the unchallenged, IrrPb immunized mice produced detectable levels of splenic IFN-γ when stimulated in vitro with Pb-A antigen. While the source of this splenic IFN-γ produced upon immunization with IrrPb was not studied, we cannot discount the possibility that antigenically primed CD 4+ T cells or some other splenic cells were responsible for the IFN-γ production through an immunological feedback mechanism, since ECM-protected IrrPb immunized mice had lower splenic IFN-γ levels after Pb-A challenge (Figure 5).

Recently, it has been proposed that immunization with subpatent doses of viable blood-stage parasites that have been genetically attenuated or curtailed by drug cure can provide protection from a virulent challenge [16], [18], [33]. These are intriguing findings, and may in part be linked to the degree to which the attenuated parasites are able to replicate and persist to stimulate the immune system without causing severe disease symptoms. In the current study, even the largest inoculums of irradiated parasites fell below the limit of blood-smear detection within a few days, suggesting that these parasites were capable of little or no replication. This level of attenuation was necessary because it appeared that replication competent blood-stage Pb-A also remained virulent to produce fulminant infections and severe disease. In another study, genetically attenuated, blood-stage Pb-A parasites that retained an ability to replicate carried a very high risk of severe disease themselves, although mice that survived the initial vaccination developed robust immunity against both parasites and disease during subsequent challenge infections [14]. In the current study, low numbers of the non-replicating parasites failed to induce anti-parasite or anti-disease immunity.

Although immunization with a high dose of irradiated Pb-A protected mice against ECM in this study, the protected mice still accumulated CD8 T cells in their brain vasculature similar to ECM-susceptible mice. Previous studies have shown that brain sequestered CD8 T cells are necessary but not sufficient for ECM in the Pb-A model [34], [35], [36], [37]. Similar to this study, perforin-deficient mice that were resistant to ECM still accumulated activated effector CD8 T cells (CD44+, CD62L−, CD69+) in their brains [35]. Further experimentation will be needed to explore the mechanism of ECM resistance induced by irradiated blood stage parasites.

In summary, inline with our results in the P. berghei model, it is possible that a single inoculation with a high dose of replication-deficient P. falciparum parasites might protect children in endemic areas from parasite burden and/or cerebral malaria. In either scenario, such a vaccine might lower the prospect of death from severe malaria during their vulnerable early years and thus provide them with the opportunity to develop clinical immunity after continued parasite exposure.


We thank Yamei Gao (FDA) for instruction on mouse brain perfusion and dissection. We thank Drs. Sumathi Rajagopalan (NIAID, NIH) and Danielle Turley (FDA) for assistance with parasite irradiation and cell staining. We thank Howard Mostowski (FDA CBER Flow Cytometry facility) for multicolor flow cytometry.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by intramural funding from the Food and Drug Administration and no external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Pinzon-Charry A, Good MF. Malaria vaccines: the case for a whole-organism approach. Expert Opin Biol Ther. 2008;8:441–448. [PubMed]
2. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Human Vaccines. 2010;6:97–106. [PubMed]
3. Mikolajczak SA, Aly AS, Kappe SH. Preerythrocytic malaria vaccine development. Curr Opin Infect Dis. 2007;20:461–466. [PubMed]
4. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185:1155–1164. [PubMed]
5. Vanderberg JP. Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine. 2009;27:2–9. [PMC free article] [PubMed]
6. Purcell LA, Wong KA, Yanow SK, Lee M, Spithill TW, et al. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine. 2008;26:4880–4884. [PMC free article] [PubMed]
7. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol. 2004;172:2487–2495. [PubMed]
8. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005;433:164–167. [PubMed]
9. Vaughan AM, Wang RB, Kappe SHI. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Human Vaccines. 2010;6:107–113. [PubMed]
10. VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A. 2009;106:13004–13009. [PubMed]
11. Good MF. The hope but challenge for developing a vaccine that might control malaria. Eur J Immunol. 2009;39:939–943. [PubMed]
12. Sadun EH, Wellde BT, Hickman RL. Resistance produced in owl monkeys (Aotus trivirgatus) by inoculation with irradiated Plasmodium falciparum. Mil Med. 1969;134:1165–1175. [PubMed]
13. Wellde BT, Sadun EH. Resistance produced in rats and mice by exposure to irradiated Plasmodium berghei. Exp Parasitol. 1967;21:310–324. [PubMed]
14. Spaccapelo R, Janse CJ, Caterbi S, Franke-Fayard B, Bonilla JA, et al. Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria. Am J Pathol. 2010;176:205–217. [PubMed]
15. Ting LM, Gissot M, Coppi A, Sinnis P, Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med. 2008;14:954–958. [PubMed]
16. Aly AS, Downie MJ, Mamoun CB, Kappe SH. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell Microbiol 2010 [PubMed]
17. Belnoue E, Voza T, Costa FT, Gruner AC, Mauduit M, et al. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol. 2008;181:8552–8558. [PubMed]
18. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610–617. [PubMed]
19. Engwerda C, Belnoue E, Gruner AC, Renia L. Experimental models of cerebral malaria. Curr Top Microbiol Immunol. 2005;297:103–143. [PubMed]
20. Oakley MS, Majam V, Mahajan B, Gerald N, Anantharaman V, et al. Pathogenic roles of CD14, galectin-3, and OX40 during experimental cerebral malaria in mice. PLoS ONE. 2009;4:e6793. [PMC free article] [PubMed]
21. Pais TF, Chatterjee S. Brain macrophage activation in murine cerebral malaria precedes accumulation of leukocytes and CD8+ T cell proliferation. J Neuroimmunol. 2005;163:73–83. [PubMed]
22. Mahajan B, Berzofsky JA, Boykins RA, Majam V, Zheng H, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun. 2010;78:4613–4624. [PMC free article] [PubMed]
23. Curfs JH, Hermsen CC, Meuwissen JH, Eling WM. Immunization against cerebral pathology in Plasmodium berghei-infected mice. Parasitology. 1992;105(Pt 1):7–14. [PubMed]
24. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: A convergence of evidence. Hum Vaccin. 2010;6 [PubMed]
25. Hughes HP, Dixon B. Vaccination of chicks against Plasmodium gallinaceum by erythrocytic and exoerythrocytic parasites attenuated by gamma irradiation. Ann Trop Med Parasitol. 1980;74:115–126. [PubMed]
26. Wellde BT, Diggs CL, Anderson S. Immunization of Aotus trivirgatus against Plasmodium falciparum with irradiated blood forms. Bull World Health Organ. 1979;57(Suppl 1):153–157. [PubMed]
27. Hansen DS, Bernard NJ, Nie CQ, Schofield L. NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol. 2007;178:5779–5788. [PubMed]
28. Augustine AD, Hall BF, Leitner WW, Mo AX, Wali TM, et al. NIAID workshop on immunity to malaria: addressing immunological challenges. Nat Immunol. 2009;10:673–678. [PubMed]
29. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13–36, Table of Contents. [PMC free article] [PubMed]
30. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9:725–732. [PubMed]
31. Schofield L. Intravascular infiltrates and organ-specific inflammation in malaria pathogenesis. Immunol Cell Biol. 2007;85:130–137. [PubMed]
32. Mitchell AJ, Hansen AM, Hee L, Ball HJ, Potter SM, et al. Early cytokine production is associated with protection from murine cerebral malaria. Infect Immun. 2005;73:5645–5653. [PMC free article] [PubMed]
33. Elliott SR, Kuns RD, Good MF. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun. 2005;73:2478–2485. [PMC free article] [PubMed]
34. Baptista FG, Pamplona A, Pena AC, Mota MM, Pied S, et al. Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect Immun. 2010;78:4033–4039. [PMC free article] [PubMed]
35. Nitcheu J, Bonduelle O, Combadiere C, Tefit M, Seilhean D, et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol. 2003;170:2221–2228. [PubMed]
36. Amante FH, Haque A, Stanley AC, Rivera Fde L, Randall LM, et al. Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria. J Immunol. 2010;185:3632–3642. [PubMed]
37. Claser C, Malleret B, Gun SY, Wong AY, Chang ZW, et al. CD8+ T cells and IFN-gamma mediate the time-dependent accumulation of infected red blood cells in deep organs during experimental cerebral malaria. PLoS ONE. 2011;6:e18720. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science